BLENREP

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaAmyloidosisAL AmyloidosisRelapsed/refractory Multiple MyelomaRecurrent Multiple MyelomaPlasma Cell MyelomaRelapse Multiple MyelomaMyelomaRefractory Multiple MyelomaMyeloma Multiple

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Empliciti

Bristol-Myers Squibb

Phase 3

452

Biaxin

AbbVie

Phase 3

153

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

294

Treanda

AAzurity Pharmaceuticals

Phase 3

195

Vepesid

AAvyxa

Phase 3

176

Mozobil

GGenzyme, a Sanofi Company

Phase 3

157

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

108

Sylvant

RRECORDATI GROUP

Phase 3

89

Mezigdomide

Bristol-Myers Squibb

Phase 3

1110

Etentamig

AbbVie

Phase 3

8Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Myeloma10 trials

A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)

Recruiting·GSK·Phase 2·NCT07227311·200 enrolled

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Recruiting·GSK·Preclinical·NCT05714839·123 enrolled

Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05556798·9 enrolled

Show 7 more trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Recruiting·KKaryopharm Therapeutics Inc·Preclinical·NCT02343042·300 enrolled

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Active, not recruiting·GSK·Phase 3·NCT04162210·325 enrolled

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

Active, not recruiting·GSK·Phase 1·NCT04398745·36 enrolled

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 7 - Belantamab Mafodotin, Nirogacestat, Pomalidomide, and Dexamethasone in Combination

Active, not recruiting·GSK·Preclinical·NCT07150104·14 enrolled

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination

Active, not recruiting·GSK·Preclinical·NCT07217119·25 enrolled

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination

Active, not recruiting·GSK·Preclinical·NCT07217184·30 enrolled

A Phase 2, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Alternative and Approved Dosing Regimens of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

Not yet recruiting·GSK·Phase 2·NCT07614360·150 enrolled

Plasma Cell Myeloma2 trials

Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In

Recruiting·EEmory University·Phase 2·NCT05208307·34 enrolled

Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Positivity After Autologous Stem Cell Transplantation

Active, not recruiting·RRoswell Park Cancer Institute·Phase 2·NCT04876248·4 enrolled

Recurrent Multiple Myeloma2 trials

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Suspended·AAlliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled

Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma

Recruiting·MMayo Clinic·Phase 2·NCT05847569·62 enrolled

AL amyloidosis2 trials

A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Recruiting·UUniversity of Texas Southwestern Medical Center·Preclinical·NCT05145816·37 enrolled

A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Completed·SStichting European Myeloma Network·Phase 2·NCT04617925·35 enrolled

Relapse Multiple Myeloma2 trials

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

Not yet recruiting·MMontefiore Medical Center·Phase 1·NCT07720843·50 enrolled

Retrospective Observational Study to Evaluate the Effectiveness and Safety of Belantamab Mafodotin-based Combinations (Belantamab Mafodotin, Bortezomib, Dexamethasone [BVd] or Belantamab Mafodotin, Pomalidomide, Dexamethasone [BPd]) Used as Compassionate Use in Patients With Multiple Myeloma in First or Second Relapse

Not yet recruiting·PPETHEMA Foundation··NCT07637526·100 enrolled

5 more indications

Relapsed/Refractory Multiple Myeloma1 trial

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

Not yet recruiting·CCristiana Costa Chase, DO·Phase 2·NCT05874193·33 enrolled

Myeloma Multiple1 trial

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05091372·94 enrolled

Myeloma1 trial

Phase 2 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant Consolidation and Maintenance for Multiple Myeloma

Active, not recruiting·UUniversity of Pennsylvania·Phase 2·NCT04680468·41 enrolled

Refractory Multiple Myeloma1 trial

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy With Reduced Versus Standard Dose of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (REBEL)

Not yet recruiting·PPolish Myeloma Consortium·Phase 2·NCT07748689·228 enrolled

Amyloidosis1 trial

A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)

Recruiting·GSK·Phase 2·NCT07224672·60 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News